News
Pfizer and BioNTech select lead mRNA vaccine against COVID-19
Pfizer and BioNTech have started a global Phase II/III safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine programme against SARS-CoV-2.